Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 15;8(1):e148.
doi: 10.1017/cts.2024.622. eCollection 2024.

The future is now: Using the lessons learned from the ACTIV COVID-19 therapeutics trials to create an inclusive and efficient clinical trials enterprise

Stacey J Adam  1 , Sarah E Dunsmore  2 , Lisa H Merck  3 , Sarah W Read  4 , Yves Rosenberg  5
Affiliations
Editorial

The future is now: Using the lessons learned from the ACTIV COVID-19 therapeutics trials to create an inclusive and efficient clinical trials enterprise

Stacey J Adam et al. J Clin Transl Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no disclosures to make.

Figures

Figure 1.
Figure 1.
Timeline of COVID-19 therapeutic milestones.
Figure 2.
Figure 2.
Key lessons learned themes discussed in each of the ACTIV manuscripts. ACTIV = Accelerating COVID-19 Therapeutic Interventions and Vaccines; DCR = Department of Clinical Research; DSMB = Data and Safety Monitoring Board; GGP-EP = good participatory practice guidelines.
See this image and copyright information in PMC

References

    1. Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov 2021;20: 254–255. doi: 10.1038/d41573-021-00037-3. - DOI - PubMed
    1. Collins FS, Stoffels P. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323: 2455–2457. doi: 10.1001/jama.2020.8920. - DOI - PubMed
    1. Buchman TG, Draghia-Akli R, Adam SJ, et al. Accelerating coronavirus disease 2019 therapeutic interventions and vaccines-selecting compounds for clinical evaluation in coronavirus disease 2019 clinical trials. Crit Care Med. 2021;1: 1963–1973. doi: 10.1097/CCM.0000000000005295. - DOI - PMC - PubMed
    1. LaVange L, Adam SJ, Currier JS, et al. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): designing master protocols for evaluation of candidate COVID-19 therapeutics. Ann Intern Med. 2021;174: 1293–1300. doi: 10.7326/M21-1269. - DOI - PMC - PubMed
    1. Wang H, Paulson KR, Pease SA, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 2022;399: 1513–1536. doi:10.1016/S0140-6736(21)02796-3. - DOI - PMC - PubMed

Publication types

LinkOut - more resources